Open access
Sep 2026
Cardiovascular risk lowering during therapy with an SPC amlodipine/atorvastatin/ perindopril: post-hoc analysis of TARGET study results
CV risk descrease was significantly associated with target BP achievement of <140/90 mm Hg which highlights the key role of BP control in the overall strategy of CV risk mitigation and demonstrates potential advantages of this multitarget polypill in real clinical practice.
I. E. Сhazova, Y. Khomitskaya, B. Kvasnikov et al.
· Eurasian heart journal · 0 citations